Investor Profile: .406 Ventures — Thesis, Cheque Size & How to Apply

.406 Ventures funding is for early-stage founders in healthcare, data and AI, and cybersecurity who want a lead investor with two decades of company-building behind it. If you are asking how to get funding from .406 Ventures, know that the Boston firm leads or co-leads first institutional rounds, and has done so since 2005, when its founders set out to fill a gap in Boston’s early-stage funding market. It now manages over $1.3 billion and marked its 100th portfolio investment in 2026.

.406 Ventures funding: thesis and stage focus

.406 Ventures invests in pioneering healthcare, data and AI, and cybersecurity companies founded by visionary entrepreneurs, focusing primarily on the eastern half of the United States. Its sweet spot is the first institutional round: it leads or co-leads early-stage investments in market-changing companies and backs world-class operators who move quickly. The firm’s fifth core fund, Point 406 Ventures V, raised in February 2024, invests in companies solving the biggest problems in healthcare, data and AI, and cybersecurity.

Fund size and cheque size

.406 Ventures raised $265 million for Point 406 Ventures V, its fifth core fund, and by September 2026 had raised more than $1.3 billion across five core funds and three opportunity funds. An individual cheque size is not publicly disclosed by the firm, so no per-deal figure is claimed here. Its fourth fund closed oversubscribed at $294 million in 2019, above a $225 million target. The firm has also backed six unicorns over its twenty years.

Notable portfolio companies

The firm’s 100th portfolio company is Teal Health, a women’s healthcare company making cervical cancer screening more accessible through an at-home option, announced in September 2026. Its notable lead investments include AbleTo, acquired by Optum; Carbon Black, acquired by VMware; CloudHealth, acquired by VMware; Health Dialog, acquired by BUPA; Iora Health, acquired by One Medical and Amazon; MineralTree, acquired by Global Payments; Veracode, acquired by CA Technologies; and Reltio, acquired by SAP, whose Series A the firm co-led in 2015.

Team and support

.406 Ventures was founded by Liam Donohue, Maria Cirino and Larry Begley, with Donohue serving as co-founder and managing partner. In September 2026 the firm promoted Kathryn Taylor Reddy from principal to partner; her portfolio work spans Bluebird Kids Health, Cortica, Diana Health, FamilyWell Health, Helm, InStride Health, Lynx, On Belay Health, OncoveryCare and Teal Health. The firm runs no public accelerator programme; its model is concentrated, hands-on, lead-investor support for a relatively small number of companies — 100 across twenty years.

How to apply for funding

.406 Ventures does not publish an open application form, so the verified route is to approach the firm through its own site, 406ventures.com, or its published contact route, [email protected], ideally with a warm introduction from a portfolio founder, co-investor or operator in its healthcare, data and AI, or cybersecurity networks. Founders should arrive with a first-institutional-round story: a differentiated technology platform, a large market and a visionary team. Given its eastern US focus, founders based there should say so plainly.